ReviewThe Journal of clinical investigation2026

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.

Ryan J Jalleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.